Switching From Rosiglitazone: Thinking Outside the Class

Lipska, Kasia J.; Ross, Joseph S.
February 2011
JAMA: Journal of the American Medical Association;2/23/2011, Vol. 305 Issue 8, p820
Academic Journal
The authors reflect on the risks involved among diabetics who decided to switch their medication from rosiglitazone to pioglitazone. They note the importance for physicians and patients to weight the benefits and risks of therapy when making treatment decisions. They also cite the current consensus of the American Diabetes Association and European Association for the Study of Diabetes in which therapeutic recommendations are based on surrogate outcomes.


Related Articles

  • 'Father of the Year': An ADA tradition continues.  // Westchester County Business Journal;6/2/2008, Vol. 47 Issue 22, p38 

    The article features the Father of the Year Award given by the American Diabetes Association (ADA). The National Father's Day Council, a nonprofit organization created to enhance the meaning of Father's Day, honors men whose lives revolves around family, citizenship, charity, and responsibility....

  • Diabetes forums present new findings, diagnostics, drugs. Carrell, Steve // Drug Topics;7/17/2000, Vol. 144 Issue 14, p21 

    Presents information on the presentations offered at the American Diabetes Association's 2000 60th Annual Scientific Sessions in San Antonio, Texas. Discussion on marketed blood glucose monitors; Benefits of using Nateglinide for treatment of diabetes; Information on studies from the Heart...

  • Organization Section.  // Diabetes;Jun2007, Vol. 56 Issue 6, p1748 

    A calendar of events for the 2007-2008 diabetic care program meetings is presented. The 9th International Congress of the Immunology and Diabetes Society and American Diabetes Association Research Conference will be held on November 14-18, 2007 in Miami, Florida. The Pancreatic β-cell: birth,...

  • Status of research funded by the American Diabetes Association: year 3. Davidson, Mayer B. // Diabetes;Mar2002, Vol. 51 Issue 3, p888 

    Announces the adoption of the Five Year Plan by the American Diabetes Association in the U.S. Goal of allocating one of every three dollars of total public support to research awards; Appraisal of progress toward the goal; Depiction of performance.

  • Credits, Clients and Awards.  // Fairfield County Business Journal;1/14/2008, Vol. 47 Issue 2, p19 

    The article offers news briefs related to several issues in Connecticut. It states that Bob Lederer, owner and chairman of Prime Line, was named 2008 inductee to the Promotional Products Association International Hall of Fame. Greenwich Hospital was awarded the American Diabetes Association...

  • Calling All Youth Advocates.  // Diabetes Forecast;Dec2002, Vol. 55 Issue 12, p91 

    Presents an update on diabetes advocacy in the U.S. as of December 2002. Acceptance of applications for the 2003 2004 National Youth Advocate by the American Diabetes Association; Qualifications for applicants; List of information needed to be qualified for the program.

  • Hot topics at ADA's 69th Scientific Sessions. Tanzi, Maria G. // Pharmacy Today;Sep2009, Vol. 15 Issue 9, p17 

    The article highlights the papers discussed during the 2009 American Diabetes Association 69th Annual Scientific Sessions on diabetes care in New Orleans, Louisiana. Topics focus on the long-term cardiovascular safety of rosiglitazone, an anti-diabetic drug from Avandia-GlaxoSmithKline. It also...

  • American Diabetes Association 60th Scientific Sessions, 2000: thiazolidinediones, obesity, and related topics. Bloomgarden, Zachary T.; Bloomgarden, Z T // Diabetes Care;Jan2001, Vol. 24 Issue 1, p162 

    Part II. Covers topics that were discussed at the annual meeting of the American Diabetes Association held in San Antonio, Texas in June 2000. Obesity and risk of diabetes; Hepatic safety of thiazolidinediones; Peroxisome proliferator-activated receptors.

  • Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Singh, Sonal; Furberg, Curt D. // Heart;Jan2009, Vol. 95 Issue 1, p1 

    The article focuses on the study of thiazolidinediones and cardiovascular outcomes in type 2 diabetes conducted by the American Diabetes Association and the European Association for the Study of Diabetes Update. The unfavorable findings from the three trials reported in June 2008 have not been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics